MX2011009804A - Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. - Google Patents

Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.

Info

Publication number
MX2011009804A
MX2011009804A MX2011009804A MX2011009804A MX2011009804A MX 2011009804 A MX2011009804 A MX 2011009804A MX 2011009804 A MX2011009804 A MX 2011009804A MX 2011009804 A MX2011009804 A MX 2011009804A MX 2011009804 A MX2011009804 A MX 2011009804A
Authority
MX
Mexico
Prior art keywords
ave5026
patients
dose
treatment
renal impairment
Prior art date
Application number
MX2011009804A
Other languages
English (en)
Inventor
Pierre-Francois Clot
Catherine Dubruc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011009804A publication Critical patent/MX2011009804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La invención se refiere a una dosis de 10 mg de AVE5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
MX2011009804A 2009-03-19 2010-03-18 Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. MX2011009804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290202A EP2233145A1 (en) 2009-03-19 2009-03-19 A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
PCT/IB2010/051186 WO2010106519A1 (en) 2009-03-19 2010-03-18 A dose of ave5026 for the treatment of venous thromboembolism in patients with severe renal impairment

Publications (1)

Publication Number Publication Date
MX2011009804A true MX2011009804A (es) 2011-09-29

Family

ID=40750891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009804A MX2011009804A (es) 2009-03-19 2010-03-18 Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.

Country Status (16)

Country Link
US (1) US20120046241A1 (es)
EP (2) EP2233145A1 (es)
JP (1) JP2012520869A (es)
KR (1) KR20110134410A (es)
CN (1) CN102355903A (es)
AR (1) AR075866A1 (es)
AU (1) AU2010224510A1 (es)
BR (1) BRPI1009322A2 (es)
CA (1) CA2755726A1 (es)
IL (1) IL215138A0 (es)
MX (1) MX2011009804A (es)
RU (1) RU2011142152A (es)
SG (1) SG174433A1 (es)
TW (1) TW201038279A (es)
UY (1) UY32507A (es)
WO (1) WO2010106519A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399590A1 (en) * 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
EP2399592A1 (en) * 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP2399591A1 (en) * 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
EP2399593A1 (en) * 2010-06-28 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in orthopaedic surgery with improved benefit-risk profile
WO2012072799A1 (en) * 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
FR2845686B1 (fr) 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
EP1568372A1 (en) * 2004-02-26 2005-08-31 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment

Also Published As

Publication number Publication date
EP2408459A1 (en) 2012-01-25
EP2233145A1 (en) 2010-09-29
RU2011142152A (ru) 2013-04-27
US20120046241A1 (en) 2012-02-23
KR20110134410A (ko) 2011-12-14
SG174433A1 (en) 2011-10-28
CA2755726A1 (en) 2010-09-23
UY32507A (es) 2010-10-29
AU2010224510A1 (en) 2011-10-06
JP2012520869A (ja) 2012-09-10
TW201038279A (en) 2010-11-01
IL215138A0 (en) 2011-12-29
BRPI1009322A2 (pt) 2019-09-24
WO2010106519A1 (en) 2010-09-23
AR075866A1 (es) 2011-05-04
CN102355903A (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
IN2014CN02616A (es)
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
TW201711676A (en) Ferric citrate dosage forms
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2011007930A (es) Conjugados de insulina cristalina.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX2014004862A (es) Formulaciones de polimero acrilico.
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
GB2482817A (en) Novel use
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
IL217527A0 (en) Fulvestrant in a dosage of 500 mg for the treatment of advanced breast cancer
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
EA201070295A1 (ru) Лечение рака легких
TW200738229A (en) Memantine for the normalization of visual acuity deficits
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
UA48940U (ru) СПОСОБ ЛЕЧЕНИЯ ДУОДЕНАЛЬНОЙ ЯЗВЫ С СОПУТСТВУЮЩИМ ХРОНИЧЕСКИМ БРОНХИТОМ У ЛИЦ|личности| МОЛОДОГО ВОЗРАСТА
UA44831U (ru) Способ лечения женщин, больных гипертонической болезнью в сочетании с сахарным диабетом ii типа
UA45538U (ru) Способ лечения астенического синдрома у пациентов урологического профиля
RU2010132592A (ru) Способ лечения начальных стадий прогрессирующего птеригиума
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период

Legal Events

Date Code Title Description
FA Abandonment or withdrawal